Playtex Q3
This article was originally published in The Rose Sheet
Executive Summary
Preliminary guidance anticipates net sales will increase 3%-4% in 2004, with firm's sun care division achieving similar results, Playtex CFO Glenn Forbes predicts during company's Q3 sales and earnings announcement Oct. 28. Playtex' sun care sales were "minimal" in the quarter at $2.3 mil., firm says. Company's net sales decreased 7.1% to $150.1 mil., while net earnings were down 64.7% to $3.13 mil. However, Playtex is optimistic launches next year will restore growth. These include revamped Kids product range with an SPF 50 extension, Suntanicals additions such as SPF 30 sunscreen and after sun lotion, and Surf SPF 30 waterproof sunblock (1"The Rose Sheet" Oct. 20, 2003, Marketing In Brief). Playtex expects the launch of Beyond Tampons,which begin shipping in Q1,to fill a niche in the feminine care market, and benefit sales...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.